Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | New and emerging drug targets for older AML patients

Nigel Russell • 14 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Cytarabine Magrolimab Venetoclax
VIALE-A

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores new and emerging drug targets for acute myeloid leukemia (AML). Specifically discussed by Dr Russell is the use of venetoclax with azacitidine, updates in the VIALE-A study (NCT02993523) and magrolimab, an anti-CD47 antibody. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nigel Russell

1:02
AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
Nigel Russell • 10 Jun 2023
1:21
Gemtuzumab-based induction chemotherapy with midostaurin in FLT3-mutated AML
Nigel Russell • 10 Jun 2023
1:52
AML19 update: improvement in OS in patients with NPM1-mutated AML treated with FLAG-Ida-GO
Nigel Russell • 10 Jun 2023
3:26
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
Nigel Russell • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals